20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines

20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines

Active immunization during infancy and early childhood represents the cornerstone of pediatric preventive medicine and public health. The Advisory Committee on Immunization Practices (ACIP)—working in harmonized collaboration with the American Academy of Pediatrics (AAP) and the American Academy of Family Physicians (AAFP)—annually updates the recommended childhood immunization schedule. Pediatric clinical pharmacists must master the precise minimum ages, minimum intervals, formulation differences, high-risk indications, and absolute contraindications that define safe vaccine stewardship from birth through age 6.

---

Master Childhood Immunization Reference Table (Birth through 6 Years)

---

Hepatitis B (HepB) Prevention Protocols from Birth

Perinatal transmission of hepatitis B virus results in chronic infection in up to 90% of infected neonates, predisposing them to cirrhosis and hepatocellular carcinoma. Prevention relies on timely immunization and post-exposure prophylaxis initiated within hours of delivery.

[!IMPORTANT] December 16, 2025 change — know which half of the algorithm moved. On that date the CDC adopted ACIP's recommendation of individual-based decision-making (termed shared clinical decision-making on the immunization schedule) for the hepatitis B birth dose in infants born to mothers who test NEGATIVE for HBsAg. The parent and clinician weigh vaccine benefits, vaccine risks, and infection risks — for example a household contact with hepatitis B. When the birth dose is deferred, CDC guidance is that the first dose be given no earlier than 2 months of age. Coverage through the Vaccines for Children Program, CHIP, Medicaid, Medicare, and Marketplace plans is unchanged.

Nothing changed for infants born to HBsAg-positive mothers or mothers of unknown status. Those infants still receive the birth dose of vaccine (plus HBIG where indicated) within 12 hours of birth. ACIP separately recommended that all pregnant women be tested for HBsAg, which is what makes the negative-mother pathway safe to individualize. Note that the printed CDC schedule notes lag these votes; date any conflicting source before answering.

Neonatal Hepatitis B Immunization Decision Tree:

                               [Infant Delivered]
                                       │
            ┌──────────────────────────┴──────────────────────────┐
            ▼                                                     ▼
 [Maternal HBsAg Positive]                             [Maternal HBsAg Negative]
            │                                                     │
 ┌──────────┴──────────┐                               ┌──────────┴──────────┐
 ▼                     ▼                               ▼                     ▼
[Infant >= 2,000 g]   [Infant < 2,000 g]             [Infant >= 2,000 g]   [Infant < 2,000 g]
 • HepB Vaccine +      • HepB Vaccine +                • Individual-based    • Individual-based
   HBIG within           HBIG within                     decision-making:      decision-making;
   12 hr (separate       12 hr (separate                 birth dose OR         if deferred, no
   limbs)                limbs)                          defer (no earlier     earlier than age
                                                         than age 2 mo)        2 mo; otherwise
                                                       • If given at birth,     delay to hospital
                                                         counts as Dose 1       discharge/1 mo
 • Birth dose          • Birth dose does                                     • If medically
   counts as             NOT count in                                          stable, 3 doses
   Dose 1                3-dose series                                         starting at 1 mo
 • Complete 3 doses    • Complete 3 addtl
 • PVST at 9-12 mo       doses starting at 1 mo
                       • PVST at 9-12 mo

1. Maternal HBsAg-Positive Protocol (Unchanged — Time-Critical)

• Immediate Dual Prophylaxis: Within 12 hours of birth, administer monovalent Hepatitis B vaccine (0.5 mL IM) AND Hepatitis B Immune Globulin (HBIG, 0.5 mL IM) at separate anatomical sites (e.g., opposite anterolateral thighs).
• Infants Weighing <2,000 grams: The birth dose does NOT count toward the required 3-dose series due to reduced immunogenicity in premature neonates. These infants must receive a total of 4 doses (birth dose + 3 additional doses administered at chronological ages 1 month, 2 to 3 months, and 6 months).
• Infants Weighing >=2,000 grams: The birth dose counts as Dose 1 of the 3-dose series (subsequent doses at 1–2 months and 6 months).
• Post-Vaccination Serologic Testing (PVST): Must be performed at 9 to 12 months of age (or 1 to 2 months after completing the series if delayed). Testing includes anti-HBs (protective if >=10 mIU/mL) and HBsAg (detects chronic infection). Testing should never occur before 9 months to avoid detecting passively acquired maternal anti-HBs or transient post-vaccination HBsAg antigenemia.

2. Maternal HBsAg Status Unknown Protocol

• Infant >=2,000 grams: Administer monovalent HepB vaccine within 12 hours of birth. Immediately test maternal blood for HBsAg. If the mother tests positive, administer HBIG as soon as possible, but no later than 7 days of age.
• Infant <2,000 grams: Because of high vulnerability and suboptimal response, administer both HepB vaccine AND HBIG (0.5 mL) within 12 hours of birth. The birth dose does not count toward the 3-dose series.

3. Absolute Timing Rules for the Final HepB Dose

The final dose (dose 3 or 4) in the Hepatitis B series must satisfy three mandatory criteria:

1. Minimum chronological age of 24 weeks (164 days).
2. Minimum interval of 16 weeks after dose 1.
3. Minimum interval of 8 weeks after dose 2.

---

Rotavirus Vaccines: Formulation Distinctions & Inflexible Windows

Rotavirus is the leading cause of severe dehydrating gastroenteritis in infants worldwide. Two live oral rotavirus vaccines are licensed in the United States, each following distinct schedules:

Rotavirus Formulation Comparison & Administration Boundaries:

┌─────────────────────────────┬────────────────────────────────────────────────────────┐
│ Parameter                   │ RV5 (RotaTeq)             │ RV1 (Rotarix)              │
├─────────────────────────────┼───────────────────────────┼────────────────────────────┤
│ Antigen Composition         │ Pentavalent human-bovine  │ Monovalent human live      │
│                             │ reassortant (G1-G4, P1A)  │ attenuated (G1P[8])        │
│ Routine Schedule            │ 3 doses: 2, 4, 6 months   │ 2 doses: 2, 4 months       │
│ Administration Route/Volume │ Oral liquid (2.0 mL tube) │ Oral liquid (1.5 mL app)   │
│ Latex in Applicator         │ Latex-free                │ Natural rubber latex tip   │
│ Minimum Age for Dose 1      │ 6 weeks 0 days            │ 6 weeks 0 days             │
│ MAXIMUM Age for Dose 1      │ 14 weeks 6 days (strict)  │ 14 weeks 6 days (strict)   │
│ MAXIMUM Age for Final Dose  │ 8 months 0 days (strict)  │ 8 months 0 days (strict)   │
│ Minimum Dosing Interval     │ 4 weeks                   │ 4 weeks                    │
└─────────────────────────────┴───────────────────────────┴────────────────────────────┘

Inflexible ACIP Age Boundaries

• Dose 1 Cutoff: The maximum age for administering Dose 1 is 14 weeks 6 days (104 days). If an infant reaches 15 weeks 0 days without receiving Dose 1, rotavirus vaccine MUST NOT be initiated. Clinical safety data demonstrate an increased attributable risk of intussusception when the initial dose is given to older infants.
• Final Dose Cutoff: The maximum age for the final dose (Dose 2 for RV1 or Dose 3 for RV5) is 8 months 0 days. Any remaining doses are omitted once the infant turns 8 months 0 days, regardless of series completion.
• Brand Interruption: If any dose in the series is RV5, or if the brand is unknown, a total of 3 doses must be administered.

Absolute Contraindications & Precautions

• Absolute Contraindication 1: Severe Combined Immunodeficiency (SCID). Live rotavirus vaccine can cause protracted wild-type-like viral replication and fatal diarrhea in SCID patients.
• Absolute Contraindication 2: History of Intussusception. A documented prior episode of intussusception permanently precludes all rotavirus vaccination due to the risk of recurrence (attributable risk of ~1 to 5 excess cases per 100,000 vaccinated infants, peaking within 3 to 7 days post-dose 1).
• Precautions: Spina bifida or bladder exstrophy (Rotarix applicator contains natural rubber latex); acute moderate-to-severe gastroenteritis (defer until illness resolves); altered immunocompetence other than SCID.

---

DTaP: Schedule, Contraindications & Precautionary Algorithms

DTaP (Diphtheria and Tetanus toxoids and acellular Pertussis) is approved strictly for children younger than 7 years of age (6 weeks through 6 years). For children aged 7 years and older, Tdap or Td is utilized.

5-Dose Routine Schedule

• Doses 1, 2, 3: Administered at 2, 4, and 6 months of age (minimum age 6 weeks; minimum interval 4 weeks).
• Dose 4: Administered at 15 to 18 months of age (minimum interval 6 months after dose 3). Accelerated Rule: Dose 4 can be administered as early as 12 months of age provided at least 6 months have elapsed since dose 3 and the child is unlikely to return at 15–18 months.
• Dose 5: Administered at 4 to 6 years of age prior to school entry. Omission Rule: If Dose 4 was administered on or after the child's 4th birthday and at least 6 months after Dose 3, Dose 5 is not required.

Absolute Contraindications vs. Precautions

Safety Triaging for Pertussis-Containing Vaccines (DTaP / Tdap):

┌──────────────────────────────────────────────────────────────────────────────────────┐
│ ABSOLUTE CONTRAINDICATIONS (Permanently Precludes Future Pertussis Antigens)         │
├──────────────────────────────────────────────────────────────────────────────────────┤
│ 1. Severe immediate anaphylaxis to a prior vaccine dose or vaccine component.        │
│ 2. Encephalopathy (e.g., coma, prolonged seizures, altered consciousness) within     │
│    7 days of a prior pertussis vaccine not attributable to another cause.           │
│    ► Action: Substitute DT (Diphtheria-Tetanus) for all remaining doses.             │
└──────────────────────────────────────────────────────────────────────────────────────┘

┌──────────────────────────────────────────────────────────────────────────────────────┐
│ PRECAUTIONS (Require Risk-Benefit Analysis; Pertussis May Be Deferred or Given)      │
├──────────────────────────────────────────────────────────────────────────────────────┤
│ • Progressive, unstable neurologic disorder (uncontrolled epilepsy, infantile        │
│   spasms) ► Defer until neurologic status is clarified and stabilized.              │
│ • Temperature >= 105°F (>= 40.5°C) within 48 hours without identifiable etiology.    │
│ • Collapse or shock-like state (hypotonic-hyporesponsive episode [HHE]) within 48 hr.│
│ • Persistent, inconsolable crying lasting >= 3 hours within 48 hours.                │
│ • Convulsions with or without fever within 3 days of prior dose.                     │
│ • Guillain-Barré syndrome (GBS) within 6 weeks of prior tetanus toxoid.              │
└──────────────────────────────────────────────────────────────────────────────────────┘

---

Haemophilus influenzae type b (Hib) & Pneumococcal Conjugate (PCV15 vs. PCV20)

Hib Conjugate Vaccines: PRP-T vs. PRP-OMP

Conjugating the polyribosylribitol phosphate (PRP) capsular polysaccharide to a protein carrier transforms Hib from a T-cell-independent to a T-cell-dependent antigen, establishing robust immunological memory in infants under 2 years of age.

• PRP-T (Tetanus Toxoid Conjugate: ActHIB, Hiberix, Pentacel): Requires a 4-dose series (primary series at 2, 4, 6 months; booster at 12–15 months).
• PRP-OMP (Meningococcal Outer Membrane Protein Complex: PedvaxHIB, Vaxelis): Induces earlier bactericidal antibody titers after dose 1; requires only a 3-dose series (doses at 2 and 4 months; booster at 12–15 months; the 6-month dose is eliminated).
• Interchangeability Rule: If different brands are administered during the primary series, or if the brand is unknown, a total of 3 primary doses (at 2, 4, and 6 months) must be administered before the 12–15 month booster (4 doses total).
• Older Unimmunized Children: Hib is not routinely recommended for healthy children aged >=59 months (5 years). However, unimmunized children of any age with asplenia, sickle cell disease, HIV, complement deficiency, or undergoing chemotherapy/hematopoietic stem cell transplant (HSCT) require 1 or 2 catch-up doses.

Pneumococcal Conjugate Vaccines: PCV15 vs. PCV20

Invasive pneumococcal disease (IPD) causes bacteremia, meningitis, and pneumonia. ACIP guidelines recommend either PCV15 (Vaxneuvance) or PCV20 (Prevnar 20) for all routine childhood immunizations.

• Routine Schedule: 4 doses at 2, 4, 6, and 12 to 15 months (minimum age 6 weeks; minimum interval 4 weeks between infant doses, 8 weeks between dose 3 and 4).
• Serotype Coverage: PCV15 includes 15 capsular serotypes conjugated to CRM197 carrier protein. PCV20 contains the 15 serotypes in PCV15 plus 5 additional invasive serotypes: 8, 10A, 11A, 12F, and 15B.
• High-Risk Guidelines (Asplenia, Sickle Cell, Immunocompromised, Chronic Renal/Cardiac/Pulmonary Disease, CSF Leak, Cochlear Implants):
  • If PCV20 is used: Children who complete the 4-dose PCV20 series do NOT require supplemental 23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax 23). PCV20 provides broader coverage while conferring superior mucosal immunity and T-cell memory.
  • If PCV15 is used: High-risk children aged 2 through 18 years who complete the PCV15 series must receive 1 supplemental dose of PPSV23 at least 8 weeks after the final PCV15 dose to cover additional non-PCV15 serotypes.

---

MMR and Varicella: Live Vaccines & Febrile Seizure Kinetics

Measles, Mumps, and Rubella (MMR) and Varicella (VAR) are live attenuated viral vaccines administered subcutaneously at 12 to 15 months (Dose 1) and 4 to 6 years (Dose 2).

Combination MMRV (ProQuad) vs. Separate Injections

• Dose 1 at 12 to 23 Months: Administering combination MMRV as the initial dose results in an approximately two-fold increased risk of febrile seizures compared to administering MMR and Varicella as separate injections at the same visit. The attributable risk is approximately 1 excess febrile seizure per 2,300 to 2,600 children vaccinated, occurring characteristically 7 to 10 days post-vaccination (coinciding with peak measles viral replication and pyrexia).
• Current ACIP Recommendation (voted September 18, 2025; adopted by the CDC Acting Director): Children 12 months through 3 years of age are to be immunized against varicella with the standalone varicella vaccine given at the same visit as MMR, and MMRV is no longer recommended below age 4. This replaced the long-standing 2009-era rule, under which separate injections were merely preferred for dose 1 at 12 to 47 months and MMRV remained an option if the parent expressed a preference. ACIP also removed MMRV below age 4 from the Vaccines for Children Program. For Dose 2 at 4 to 6 years, MMRV remains appropriate because the excess febrile-seizure risk is confined to the younger first-dose age group.
• If MMRV Is Used at All: The minimum interval between two MMRV doses is 3 months.
• Source-Dating Caution: The printed CDC schedule notes still carried the older "MMRV may be used if parents or caregivers express a preference" wording after the September 2025 vote. Answer from the newer adopted recommendation and check the effective date of any source that conflicts.
• Live Vaccine Spacing Rule: If live injectable vaccines (MMR, Varicella, MMRV, Yellow Fever) are not administered on the same calendar day, they must be separated by a minimum of 28 days (4 weeks). If administered <28 days apart, the second vaccine is considered invalid and must be repeated at least 28 days after the invalid dose.

---

Practice Pearls & BCPPS Exam Traps

• Exam Trap 1: HepB in the <2,000 g Preterm Infant: Do not count the birth dose toward the 3-dose series in preterm neonates weighing <2,000 g unless the mother was documented HBsAg negative and the infant waited until discharge or 1 month of age. If given at birth to a low birth weight infant, 3 additional doses are required starting at 1 month.
• Exam Trap 2: Rotavirus Beyond 14 Weeks 6 Days: If a 16-week-old infant presents for their 2-month well-child checkup having never received a rotavirus vaccine, do not administer rotavirus vaccine. The maximum age for Dose 1 is strictly 14 weeks 6 days.
• Exam Trap 3: DTaP vs. Tdap Age Cutoff: DTaP is strictly for children <7 years old. If a 7-year-old child presents unimmunized, administer Tdap, never DTaP.
• Exam Trap 4: Influenza 2-Dose Rule: Always check past influenza history. A 4-year-old child receiving influenza vaccine for the first time requires 2 doses separated by at least 4 weeks. If they received only 1 dose in their entire life prior to July 1 of the current season, they still require 2 doses this season.